Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wellnx sued

This article was originally published in The Tan Sheet

Executive Summary

Multiple lawsuits consolidated in U.S. District Court in Boston claim the Canadian maker of Slimquick, NV and Liquid Hoodia dietary supplements made false weight-loss claims for the products and misrepresented the products' contents, the plaintiffs say Sept. 16. Wellnx's clients, now plaintiffs in the suit, were "cheated out of millions of dollars when Wellnx lied about what was in its products and what they would do to help them lose weight," says attorney David Barry of Boston-based Sugarman, Rogers, Barshak & Cohen. Independent lab testing found trace amounts or no weight-loss ingredients in Wellnx's products and clinical studies of green tea extract, the key ingredient in Slimquick and NV, show insignificant effects on weight loss, according to the lawyers' release. The National Advertising Division recommended Mississauga, Ontario-based Wellnx discontinue its claims for its Slimquick Extreme supplement due to lack of clinical data to support advertising claims (1"The Tan Sheet" July 21, 2008, p. 15)

You may also be interested in...



Slimquick Extreme Fails To Support “Clinically Proven” Claims – NAD

Clinical studies for Wellnx Life Sciences' weight-loss supplement Slimquick Extreme fail to meet standards necessary to support "clinically proven, strong, specific and quantified claims," the National Advertising Division says

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Topics

UsernamePublicRestriction

Register

PS102134

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel